| Source: |
| Type: |
| Lactate production has been linked to cancer development and progression. In normal conditions, lactate is produced in cells through a process called glycolysis, which breaks down glucose to generate energy. However, in cancer cells, this process is often upregulated, leading to increased lactate production, even in the presence of oxygen. This phenomenon is known as the Warburg effect. -Lactate is the end product of glycolysis and induces TGFβ1 upregulation and the acidic microenvironment. |
| Breast Cancer |
| 3454- | ALA, | Lipoic acid blocks autophagic flux and impairs cellular bioenergetics in breast cancer and reduces stemness |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 2388- | Ash, | Withaferin A decreases glycolytic reprogramming in breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-453 |
| 943- | BetA, | Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2738- | BetA, | Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 2304- | CUR, | Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 1864- | DCA, | MET, | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 5195- | DCA, | Rad, | Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | EMT6 |
| 951- | DHA, | Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function |
| - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 681- | EGCG, | Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models |
| - | vitro+vivo, | BC, | NA |
| 960- | HNK, | Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth |
| - | vitro+vivo, | BC, | MCF-7 | - | vitro+vivo, | BC, | MDA-MB-231 |
| 2452- | PA, | Targeting Pyruvate Kinase M2 and Hexokinase II, Pachymic Acid Impairs Glucose Metabolism and Induces Mitochondrial Apoptosis |
| - | in-vitro, | BC, | SkBr3 |
| 2409- | PTS, | Pterostilbene Induces Pyroptosis in Breast Cancer Cells through Pyruvate Kinase 2/Caspase-8/Gasdermin C Signaling Pathway |
| - | in-vitro, | BC, | EMT6 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | HC11 |
| 2341- | QC, | Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2328- | RES, | Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 |
| 3064- | RES, | Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species–Mediated Hypoxia-Inducible Factor-1α Activation |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | BC, | T47D | - | in-vitro, | Lung, | LLC1 |
| 2181- | SK, | Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa |
| 2350- | UA, | Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 2414- | β‐Ele, | Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:4 Cells:% prod#:% Target#:739 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid